Xiaohui Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohui Guo has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Gui-Zhi Lu
Department of Endocrinology, Peking University First Hospital, Beijing 100034, PR China
4 shared publications Li Shen
Department of Endocrinology, Peking University First Hospital, Beijing
4 shared publications- Youyuan Huang
Department of Endocrinology, Peking University First Hospital, Beijing 100034, PR China
4 shared publications - Chenxue Qu
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
3 shared publications Fang Zhao
The George Institute for Global Health at Peking University Health Science Center , Beijing, China
3 shared publications- Hong Zhang
Department of Endocrinology, Peking University First Hospital, Beijing 100034, PR China
3 shared publications
Latest Publications
- 1 November 2017
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 19 (11) , 675-684
Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors
Background: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal insulin (BI) in real-world settings in China. Methods: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months. Results: Age, gender, inpatient/outpatient status, body mass index, glycated hemoglobin (HbA1c) at baseline and at the end of study, T2D duration, microvascular complications, BI type, combination with insulin secretagogues, self-monitoring of blood glucose frequency, and insulin dosage, all predicted hypoglycemia. BI use generally did not induce significant weight gain (0.02 kg); weight gain with insulin detemir (−0.30 kg) was less than that with neutral protamine Hagedorn (NPH) insulin (0.20 kg) or insulin glargine (0.05 kg). Overall, general hypoglycemia incidence (5.6% vs. 7.7%) and annual event rate (1.6 vs. 1.8) were similar before and after BI initiation, whereas a slight decrease was noted in severe hypoglycemia incidence (0.6%–0.3%) and frequency (0.05–0.03 events/patient-year). The general hypoglycemia rate was lowest with insulin glargine, whereas there was no significant difference in severe hypoglycemia among the three BI groups. Overall, 3.5% of patients had at least one SAE during the study. Most SAEs were found to be unrelated to BI treatment. Conclusions: Real-world BI use, particularly insulin detemir and glargine, was associated with only slight weight gain and low hypoglycemia risk in patients with T2D in China.
- 1 November 2017
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 19 (11) , 675-684
Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors
Background: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal insulin (BI) in real-world settings in China. Methods: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months. Results: Age, gender, inpatient/outpatient status, body mass index, glycated hemoglobin (HbA1c) at baseline and at the end of study, T2D duration, microvascular complications, BI type, combination with insulin secretagogues, self-monitoring of blood glucose frequency, and insulin dosage, all predicted hypoglycemia. BI use generally did not induce significant weight gain (0.02 kg); weight gain with insulin detemir (−0.30 kg) was less than that with neutral protamine Hagedorn (NPH) insulin (0.20 kg) or insulin glargine (0.05 kg). Overall, general hypoglycemia incidence (5.6% vs. 7.7%) and annual event rate (1.6 vs. 1.8) were similar before and after BI initiation, whereas a slight decrease was noted in severe hypoglycemia incidence (0.6%–0.3%) and frequency (0.05–0.03 events/patient-year). The general hypoglycemia rate was lowest with insulin glargine, whereas there was no significant difference in severe hypoglycemia among the three BI groups. Overall, 3.5% of patients had at least one SAE during the study. Most SAEs were found to be unrelated to BI treatment. Conclusions: Real-world BI use, particularly insulin detemir and glargine, was associated with only slight weight gain and low hypoglycemia risk in patients with T2D in China.
- Open Access
- 1 September 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (35) , e7533
Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
This study, a subgroup analysis of the data from the Organization Program of DiabEtes INsulIN ManaGement study, aimed to compare the efficacy and safety profiles of acarbose and metformin used in combination with premixed insulin. This analysis included 80 and 192 patients taking only 1 oral antidiabetic drug, classified into acarbose (treated with acarbose + insulin) and metformin groups (treated with metformin + insulin), respectively. The efficacy and safety data were analyzed for within- and between-group differences. The clinical trial registry number was NCT01338376. The percentage of patients who achieved target hemoglobin A1c (HbA1c) <7% in the acarbose and metformin groups were 38.75% and 30.73%, respectively, after a 16-week treatment. The average HbA1c levels in the acarbose and metformin groups were comparable at baseline and decreased significantly in both groups at the end of the study. All 7 blood glucose decreased significantly in both groups at endpoint compared with that at baseline. Insulin consumption was higher in the metformin group in terms of total daily amount and units/kg body weight. Incidences of hypoglycemia were similar in both groups. Body weight changed significantly in both groups from baseline to endpoint, but with no significant difference between the groups. Mean scores of Morisky Medication Adherence Scale improved in both groups at endpoint. Combination of insulin with acarbose or metformin could improve glycemic control in patients with type 2 diabetes mellitus. Acarbose and metformin were found to be comparable in terms of efficacy, weight gain, and incidence of hypoglycemia.
- 1 September 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (35) , e7533
Open AccessComparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
This study, a subgroup analysis of the data from the Organization Program of DiabEtes INsulIN ManaGement study, aimed to compare the efficacy and safety profiles of acarbose and metformin used in combination with premixed insulin. This analysis included 80 and 192 patients taking only 1 oral antidiabetic drug, classified into acarbose (treated with acarbose + insulin) and metformin groups (treated with metformin + insulin), respectively. The efficacy and safety data were analyzed for within- and between-group differences. The clinical trial registry number was NCT01338376. The percentage of patients who achieved target hemoglobin A1c (HbA1c) <7% in the acarbose and metformin groups were 38.75% and 30.73%, respectively, after a 16-week treatment. The average HbA1c levels in the acarbose and metformin groups were comparable at baseline and decreased significantly in both groups at the end of the study. All 7 blood glucose decreased significantly in both groups at endpoint compared with that at baseline. Insulin consumption was higher in the metformin group in terms of total daily amount and units/kg body weight. Incidences of hypoglycemia were similar in both groups. Body weight changed significantly in both groups from baseline to endpoint, but with no significant difference between the groups. Mean scores of Morisky Medication Adherence Scale improved in both groups at endpoint. Combination of insulin with acarbose or metformin could improve glycemic control in patients with type 2 diabetes mellitus. Acarbose and metformin were found to be comparable in terms of efficacy, weight gain, and incidence of hypoglycemia.
- 1 January 2017
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 440, 1-7
CD32b expression is down-regulated on double-negative memory B cells in patients with Hashimoto's thyroiditis
- 1 January 2017
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 440, 1-7
CD32b expression is down-regulated on double-negative memory B cells in patients with Hashimoto's thyroiditis
- Open Access
- 1 January 2017
- Published by Sciaccess Publishers LLC in Journal of Rare Diseases Research & Treatment
- Vol. 2 (1) , 19-22
Parameters of obesity in polycystic ovary syndrome
Parameters of obesity in polycystic ovary syndrome, Journal of Rare Diseases Research & Treatment
- 1 January 2017
- Published by Sciaccess Publishers LLC in Journal of Rare Diseases Research & Treatment
- Vol. 2 (1) , 19-22
Open AccessParameters of obesity in polycystic ovary syndrome
Parameters of obesity in polycystic ovary syndrome, Journal of Rare Diseases Research & Treatment
- 1 November 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 40, 332-338
Increased proportions of Tc17 cells and NK cells may be risk factors for disease progression in Hashimoto's thyroiditis
- 1 November 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 40, 332-338
Increased proportions of Tc17 cells and NK cells may be risk factors for disease progression in Hashimoto's thyroiditis
- Open Access
- 24 August 2016
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 9 (1) , 1-8
Application of receiver operating characteristic curve in the assessment of the value of body mass index, waist circumference and percentage of body fat in the Diagnosis of Polycystic Ovary Syndrome in childbearing women
There are various parameters to analyze obesity, however, no standard reference to predict, screen or diagnose PCOS with various obesity parameters has been established, and the accuracy of these parameters still needs to be studied.This study was to use the receiver operating characteristic (ROC) curve to explore the different values of three obesity parameters, body mass index (BMI), waist circumference (WC) and percentage of body fat (PBF) in the diagnosis of polycystic ovary syndrome (PCOS) in Chinese childbearing women. Three hundred patients who were diagnosed with PCOS at Center of Reproductive Medicine and Genetics of Peking University First Hospital were enrolled in this study, and 110 healthy age-matched women were enrolled as controls. The characteristics of BMI, WC and PBF in PCOS patients were analyzed. Compared with the control group, all the three obesity parameters were significantly increased in PCOS group. In terms of ROC area under the curve, WC > PBF > BMI, and they were all significantly different from those of the control. At a cut-off point of 80.5 cm, WC has a sensitivity of 73.6 % and a specificity of 85 % in diagnosis of PCOS; At a cut-off point of 29 %, PBF has a sensitivity of 88.2 % and a specificity of 57.7 % in diagnosis of PCOS; and at a cut-off point of 26.6 kg/m2, BMI has a sensitivity of 54.5 % and a specificity of 98 % in diagnosis of PCOS. WC, BMI and PBF are valuable in screening and diagnosis of PCOS in Chinese childbearing women. PBF can be used to screen PCOS as it has a better sensitivity, while BMI can be used in the diagnosis of PCOS as it has a better specificity.
- 24 August 2016
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 9 (1) , 1-8
Open AccessApplication of receiver operating characteristic curve in the assessment of the value of body mass index, waist circumference and percentage of body fat in the Diagnosis of Polycystic Ovary Syndrome in childbearing women
There are various parameters to analyze obesity, however, no standard reference to predict, screen or diagnose PCOS with various obesity parameters has been established, and the accuracy of these parameters still needs to be studied.This study was to use the receiver operating characteristic (ROC) curve to explore the different values of three obesity parameters, body mass index (BMI), waist circumference (WC) and percentage of body fat (PBF) in the diagnosis of polycystic ovary syndrome (PCOS) in Chinese childbearing women. Three hundred patients who were diagnosed with PCOS at Center of Reproductive Medicine and Genetics of Peking University First Hospital were enrolled in this study, and 110 healthy age-matched women were enrolled as controls. The characteristics of BMI, WC and PBF in PCOS patients were analyzed. Compared with the control group, all the three obesity parameters were significantly increased in PCOS group. In terms of ROC area under the curve, WC > PBF > BMI, and they were all significantly different from those of the control. At a cut-off point of 80.5 cm, WC has a sensitivity of 73.6 % and a specificity of 85 % in diagnosis of PCOS; At a cut-off point of 29 %, PBF has a sensitivity of 88.2 % and a specificity of 57.7 % in diagnosis of PCOS; and at a cut-off point of 26.6 kg/m2, BMI has a sensitivity of 54.5 % and a specificity of 98 % in diagnosis of PCOS. WC, BMI and PBF are valuable in screening and diagnosis of PCOS in Chinese childbearing women. PBF can be used to screen PCOS as it has a better sensitivity, while BMI can be used in the diagnosis of PCOS as it has a better specificity.
- Open Access
- 9 March 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (3) , e0150753
Knowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes
This study was to identify current A1c understanding status among Chinese patients with type 2 diabetes, assess if knowledge of A1c affects their diabetes self-management and their glycemic control and recognize the factors influencing knowledge of A1c among patients with type 2 diabetes. A multi-center, cross-sectional survey was conducted between April and July 2010 in 50 medical centers in the Mainland China. Participants were recruited from inpatients and outpatients who were admitted to or visited those medical centers. The survey included core questions about their demographic characteristics, diabetes self-management behavior, and A1c knowledge. Overall, of 5957 patients, the percentage of patients with good understanding was 25.3%. In the multivariable logistic regression model, the variables related to the knowledge of A1c status are presented. We discovered that patients with longer diabetes duration (OR = 1.05; 95%CI = 1.04–1.06) and having received diabetes education (OR = 1.80; 95%CI = 1.49–2.17) were overrepresented in the good understanding of A1c group. In addition, compared to no education level, higher education level was statistically associated with good understanding of A1c (PP<0.001), with Eastern being highest (OR = 1.54; 95%CI = 1.32–1.80), followed by Central (OR = 1.25; 95%CI = 1.02–1.53), when referring to Western. Only a minority of patients with type 2 diabetes in China understood their A1c value. The patients who had a good understanding of their A1c demonstrated significantly better diabetes self-management behavior and had lower A1c levels than those who did not.
- 9 March 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (3) , e0150753
Open AccessKnowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes
This study was to identify current A1c understanding status among Chinese patients with type 2 diabetes, assess if knowledge of A1c affects their diabetes self-management and their glycemic control and recognize the factors influencing knowledge of A1c among patients with type 2 diabetes. A multi-center, cross-sectional survey was conducted between April and July 2010 in 50 medical centers in the Mainland China. Participants were recruited from inpatients and outpatients who were admitted to or visited those medical centers. The survey included core questions about their demographic characteristics, diabetes self-management behavior, and A1c knowledge. Overall, of 5957 patients, the percentage of patients with good understanding was 25.3%. In the multivariable logistic regression model, the variables related to the knowledge of A1c status are presented. We discovered that patients with longer diabetes duration (OR = 1.05; 95%CI = 1.04–1.06) and having received diabetes education (OR = 1.80; 95%CI = 1.49–2.17) were overrepresented in the good understanding of A1c group. In addition, compared to no education level, higher education level was statistically associated with good understanding of A1c (PP<0.001), with Eastern being highest (OR = 1.54; 95%CI = 1.32–1.80), followed by Central (OR = 1.25; 95%CI = 1.02–1.53), when referring to Western. Only a minority of patients with type 2 diabetes in China understood their A1c value. The patients who had a good understanding of their A1c demonstrated significantly better diabetes self-management behavior and had lower A1c levels than those who did not.
- 11 October 2015
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 31 (8) , 811-816
Management status and its predictive factors in patients with type 2 diabetes in China: A Nationwide Multicenter Study
Background The prevalence of type 2 diabetes in China is increasing rapidly. Appropriate management of glycemia, blood pressure and dyslipidemia in this population is a major public health concern. Objective The aim of this study was to assess metabolic control including glycated hemoglobin A1c (HbA1c), blood pressure (BP) and low density lipoprotein cholesterol (LDL‐c), in a large sample of patients with type 2 diabetes in China and to identify factors that correlated with the achievement of HbA1c, BP and LDL‐c goals (ABCs). Method A nationwide survey was conducted in 50 medical centres across China from April to July of 2010. Baseline information on demographics, medical history, HbA1c, BP and LDL‐c levels were measured in 5961 patients with type 2 diabetes. Results Mean age, body mass index (BMI) and HbA1c were 59.5 ± 1.3 years, 24.5 ± 4.1 kg/m2 and 8.3 ± 2.2%, respectively. With respect to generally accepted ABC treatment goals, 35.2% of participants had HbA1c P=0.000), higher BMI (P=0.001) and insulin use (P=0.000) were statistically significant predictors of failing to meet ABC targets. Conclusion The percentage of Chinese patients with type 2 diabetes who met recommended targets for HbA1c, BP and LDL‐c in 2010 was low. Smoking, higher BMI and insulin use were the strongest determinants of failing to meet ABC targets. Copyright © 2015 John Wiley & Sons, Ltd.
- 11 October 2015
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 31 (8) , 811-816
Management status and its predictive factors in patients with type 2 diabetes in China: A Nationwide Multicenter Study
Background The prevalence of type 2 diabetes in China is increasing rapidly. Appropriate management of glycemia, blood pressure and dyslipidemia in this population is a major public health concern. Objective The aim of this study was to assess metabolic control including glycated hemoglobin A1c (HbA1c), blood pressure (BP) and low density lipoprotein cholesterol (LDL‐c), in a large sample of patients with type 2 diabetes in China and to identify factors that correlated with the achievement of HbA1c, BP and LDL‐c goals (ABCs). Method A nationwide survey was conducted in 50 medical centres across China from April to July of 2010. Baseline information on demographics, medical history, HbA1c, BP and LDL‐c levels were measured in 5961 patients with type 2 diabetes. Results Mean age, body mass index (BMI) and HbA1c were 59.5 ± 1.3 years, 24.5 ± 4.1 kg/m2 and 8.3 ± 2.2%, respectively. With respect to generally accepted ABC treatment goals, 35.2% of participants had HbA1c P=0.000), higher BMI (P=0.001) and insulin use (P=0.000) were statistically significant predictors of failing to meet ABC targets. Conclusion The percentage of Chinese patients with type 2 diabetes who met recommended targets for HbA1c, BP and LDL‐c in 2010 was low. Smoking, higher BMI and insulin use were the strongest determinants of failing to meet ABC targets. Copyright © 2015 John Wiley & Sons, Ltd.
- 10 September 2015
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 31 (8) , 796-802
Status of basal‐supported oral therapy in Chinese type 2 diabetic patients with inadequate glycemic control on oral anti‐diabetic drugs
Background: Timely initiation and titration of basal insulin added on to oral anti‐diabetic drugs contribute to better glycemic control. However, implementation of basal‐supported oral therapy in China is not yet clear. This nationwide, prospective, 12‐week observational study was designed to explore the current status of basal‐supported oral therapy in patients with type 2 diabetes in China.Methods: Type 2 diabetic patients with inadequate glycemic control on anti‐diabetic drugs who were to start basal‐supported oral therapy with insulin glargine at outpatient clinics were enrolled from 134 hospitals in China. Both the decision to initiate basal insulin and insulin dose adjustment were at the physician's discretion. Fasting plasma glucose (FPG) and haemoglobin A1c were measured, and the starting dose of insulin were recorded at baseline. Self‐monitored fasting capillary blood glucose and the adjusting dose of insulin were collected during the study.Results: A total of 11 192 out of 13 259 enrolled patients finished the 12‐week study. FPG and haemoglobin A1c at basal‐supported oral therapy initiation were 11.2 mmol/L and 9.4%, respectively, with insulin glargine started at 0.190 IU/kg/day. Insulin dose was increased 1.8 IU in average within 12 weeks. Fifty‐nine percent of the patients achieved fasting capillary blood glucose ≤ 7.0 mmol/L. More patients achieved the glucose target in the group with lower baseline FPG level. Notable geographical differences of physicians' treatment habits in the current management of basal‐supported oral therapy were also observed.Conclusions: A great gap between everyday clinical practice and guidelines exists in China, reflected by the delayed initiation, slow dose titration and geographical differences of basal‐supported oral therapy management. A concrete guideline of basal‐supported oral therapy management is needed in the clinical application. Copyright © 2015 John Wiley & Sons, Ltd.
- 10 September 2015
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 31 (8) , 796-802
Status of basal‐supported oral therapy in Chinese type 2 diabetic patients with inadequate glycemic control on oral anti‐diabetic drugs
Background: Timely initiation and titration of basal insulin added on to oral anti‐diabetic drugs contribute to better glycemic control. However, implementation of basal‐supported oral therapy in China is not yet clear. This nationwide, prospective, 12‐week observational study was designed to explore the current status of basal‐supported oral therapy in patients with type 2 diabetes in China.Methods: Type 2 diabetic patients with inadequate glycemic control on anti‐diabetic drugs who were to start basal‐supported oral therapy with insulin glargine at outpatient clinics were enrolled from 134 hospitals in China. Both the decision to initiate basal insulin and insulin dose adjustment were at the physician's discretion. Fasting plasma glucose (FPG) and haemoglobin A1c were measured, and the starting dose of insulin were recorded at baseline. Self‐monitored fasting capillary blood glucose and the adjusting dose of insulin were collected during the study.Results: A total of 11 192 out of 13 259 enrolled patients finished the 12‐week study. FPG and haemoglobin A1c at basal‐supported oral therapy initiation were 11.2 mmol/L and 9.4%, respectively, with insulin glargine started at 0.190 IU/kg/day. Insulin dose was increased 1.8 IU in average within 12 weeks. Fifty‐nine percent of the patients achieved fasting capillary blood glucose ≤ 7.0 mmol/L. More patients achieved the glucose target in the group with lower baseline FPG level. Notable geographical differences of physicians' treatment habits in the current management of basal‐supported oral therapy were also observed.Conclusions: A great gap between everyday clinical practice and guidelines exists in China, reflected by the delayed initiation, slow dose titration and geographical differences of basal‐supported oral therapy management. A concrete guideline of basal‐supported oral therapy management is needed in the clinical application. Copyright © 2015 John Wiley & Sons, Ltd.
- 1 March 2015
- Published by Elsevier in Cellular Immunology
- Vol. 294 (1) , 33-38
The expression of Fcγ receptors in Hashimoto’s thyroiditis
- 1 March 2015
- Published by Elsevier in Cellular Immunology
- Vol. 294 (1) , 33-38
The expression of Fcγ receptors in Hashimoto’s thyroiditis